当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Abstract：

BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent licensing and availability of darunavir, etravirine and raltegravir has broadened management options available for highly treatment-experienced patients. However, data on their safety and efficacy in preventing vertical transmission are limited. METHODS:A retrospective chart review of two cases describing obstetrical, infant and treatment outcomes associated with the use of regimens that include darunavir and etravirine with or without raltegravir during pregnancy was conducted. RESULTS:We document two cases of pregnant HIV-positive women treated with antiretroviral therapy including darunavir, etravirine and raltegravir. Vertical transmission was averted and no congenital anomalies were observed. CONCLUSIONS:In the absence of human development toxicity data for these agents, these cases provide preliminary anecdotal data on their safety during pregnancy. Although the outcomes of these cases are reassuring, additional studies and registries are required to establish the safety and efficacy of these agents during pregnancy.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Jaworsky D,Thompson C,Yudin MH,Bitnun A,Brophy J,Samson L,Antoniou T,Loutfy MR

doi

10.3851/IMP1558

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

677-80

issue

4

eissn

1359-6535

issn

2040-2058

journal_volume

15

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.

    abstract：:Treatment of primary human immunodeficiency virus (HIV) infection (PHI) may provide an opportunity to achieve a long lasting suppression of viral replication. Although there is growing evidence of the benefit of treating PHI, clinical data are still very limited. Special therapeutic considerations in this clinical set...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Zala C,Salomón H,Cahn P

    更新日期：1999-01-01 00:00:00

  • HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

    abstract：:The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2951

    authors： Marra CM

    更新日期：2015-01-01 00:00:00

  • Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.

    abstract：OBJECTIVE:To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients. METHODS:This cross-sectional study involved HIV-infected patients who were either antiretroviral-naive (Group 1) or were receiving either a s...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Ghosn J,Guiguet M,Jardel C,Benyaou R,Zeller V,Simon A,Valantin MA,Amellal B,Assoumo L,Hogrel JY,Costagliola D,Katlama C,Lombès A

    更新日期：2005-01-01 00:00:00

  • Does antiviral therapy prevent hepatocellular carcinoma?

    abstract：:Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1895

    authors： Kwon H,Lok AS

    更新日期：2011-01-01 00:00:00

  • ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection.

    abstract：BACKGROUND:ITX 5061 is a highly potent small molecule inhibitor of scavenger receptor-B1, an integral transmembrane protein that is found in liver cells and is actively involved in the transport of HCV into hepatocytes. Currently, ITX 5061 is being investigated in monoinfected hepatitis C patients in a proof-of-concept...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2354

    authors： Hochreiter J,Lapham J,Wong-Staal F,McKelvy J,Sulkowski M,Glesby MJ,Johnson VA,Morse GD

    更新日期：2013-01-01 00:00:00

  • Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

    abstract：:Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, co...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2818

    authors： Deback C,Burrel S,Varnous S,Carcelain G,Conan F,Aït-Arkoub Z,Autran B,Gandjbakhch I,Agut H,Boutolleau D

    更新日期：2015-01-01 00:00:00

  • Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

    abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3281

    authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

    更新日期：2019-01-01 00:00:00

  • Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

    abstract：BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Duraffour S,Snoeck R,de Vos R,van Den Oord JJ,Crance JM,Garin D,Hruby DE,Jordan R,De Clercq E,Andrei G

    更新日期：2007-01-01 00:00:00

  • Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

    abstract：:Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from H...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Chapman LE,Mertz GJ,Peters CJ,Jolson HM,Khan AS,Ksiazek TG,Koster FT,Baum KF,Rollin PE,Pavia AT,Holman RC,Christenson JC,Rubin PJ,Behrman RE,Bell LJ,Simpson GL,Sadek RF

    更新日期：1999-01-01 00:00:00

  • Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

    abstract：BACKGROUND/AIMS:We conducted a case-control study to investigate the efficacy of interferon-alpha (IFN-alpha) and ribavirin combination therapy for patients with chronic hepatitis C and B virus (HCV/HBV) coinfection and to elucidate the interaction of these two viruses. METHODS:Forty-two chronic HCV/HBV-coinfected pat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chuang WL,Dai CY,Chang WY,Lee LP,Lin ZY,Chen SC,Hsieh MY,Wang LY,Yu ML

    更新日期：2005-01-01 00:00:00

  • Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

    abstract：:Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2222

    authors： Dustin LB,Charles ED

    更新日期：2012-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract：:Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1671

    authors： Llibre JM

    更新日期：2010-01-01 00:00:00

  • Body image is a major determinant of sexual dysfunction in stable HIV-infected women.

    abstract：BACKGROUND:Prevalence and factors associated with sexual dysfunction in HIV-positive women are poorly known. METHODS:This was a cross-sectional study in a cohort of HIV-infected women. Clinically stable women were invited to participate in a female sexual dysfunction (FSD) evaluation with Female Sexual Function Index ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Luzi K,Guaraldi G,Murri R,De Paola M,Orlando G,Squillace N,Esposito R,Rochira V,Zirilli L,Martinez E

    更新日期：2009-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2425

    authors： Calle Serrano B,Manns MP

    更新日期：2012-01-01 00:00:00

  • Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

    abstract：:There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

    更新日期：2005-01-01 00:00:00

  • Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.

    abstract：:A novel severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. We previously isolated and characterized SARS-CoV and SARS-CoV-like viruses from human and animals, respectively, suggesting that SARS could be transmitted from wild/farmed animals ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Zheng BJ,Guan Y,Hez ML,Sun H,Du L,Zheng Y,Wong KL,Chen H,Chen Y,Lu L,Tanner JA,Watt RM,Niccolai N,Bernini A,Spiga O,Woo PC,Kung HF,Yuen KY,Huang JD

    更新日期：2005-01-01 00:00:00

  • Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.

    abstract：:In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cells during sexual transmission. The compounds tested included the secon...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Njai HF,Lewi PJ,Janssen CG,Garcia S,Fransen K,Kestens L,Vanham G,Janssen PA

    更新日期：2005-01-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3036

    authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期：2016-01-01 00:00:00

  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract：BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1751

    authors： Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期：2011-01-01 00:00:00

  • Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy.

    abstract：BACKGROUND:Damage to mitochondria (mt) is a major side effect of highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI). Such damage is associated with the onset of lipodystrophy in HAART-treated HIV+ patients. To further investigate mt changes during this syndrom...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Galluzzi L,Pinti M,Guaraldi G,Mussini C,Troiano L,Roat E,Giovenzana C,Nemes E,Nasi M,Orlando G,Salomoni P,Cossarizza A

    更新日期：2005-01-01 00:00:00

  • Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

    abstract：BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Aarnoutse RE,Wasmuth JC,Fätkenheuer G,Schneider K,Schmitz K,de Boo TM,Reiss P,Hekster YA,Burger DM,Rockstroh JK

    更新日期：2003-08-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期：2009-01-01 00:00:00

  • Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

    abstract：BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat F

    更新日期：2007-01-01 00:00:00

  • The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

    abstract：BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3156

    authors： Shan M,Shen Z,Sun H,Zheng J,Zhang M

    更新日期：2017-01-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract：BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期：2008-01-01 00:00:00

  • The role of stavudine in the management of adults with HIV infection.

    abstract：:Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Moyle GJ,Gazzard BG

    更新日期：1997-12-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract：INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1834

    authors： Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期：2011-01-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract：BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3372

    authors： Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期：2020-10-22 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract：BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期：2005-01-01 00:00:00